Boltz
Public benefit corporation developing commercially-available co-folding AI models (Boltz-1) achieving AlphaFold 3-level accuracy in predicting 3D structures of biomolecular complexes. Enables structure-guided drug discovery by predicting protein-protein interactions, small-molecule binding, and biologics design.
Launched Boltz-1 in November 2024 as fully commercial model; signed multi-year collaboration with Pfizer to build exclusive models for target selection, structure prediction, and biologics design; represents foundational shift toward deployable structure-prediction tools.
No products catalogued yet. Press Refresh above to ask the research agent.
No people linked.
No citations stored yet. Run the research agent to attach per-claim sources.